SG Americas Securities LLC Raises Stock Holdings in Disc Medicine, Inc. (NASDAQ:IRON)

SG Americas Securities LLC lifted its holdings in shares of Disc Medicine, Inc. (NASDAQ:IRON) by 44.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,071 shares of the company’s stock after acquiring an additional 1,247 shares during the period. SG Americas Securities LLC’s holdings in Disc Medicine were worth $183,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of IRON. Strs Ohio grew its position in Disc Medicine by 66.7% during the 4th quarter. Strs Ohio now owns 1,000 shares of the company’s stock worth $57,000 after purchasing an additional 400 shares during the last quarter. Jennison Associates LLC acquired a new position in Disc Medicine in the 4th quarter valued at about $2,485,000. New York State Common Retirement Fund increased its position in Disc Medicine by 194.1% in the 4th quarter. New York State Common Retirement Fund now owns 9,686 shares of the company’s stock valued at $559,000 after acquiring an additional 6,393 shares during the period. Victory Capital Management Inc. lifted its position in Disc Medicine by 36.4% during the 4th quarter. Victory Capital Management Inc. now owns 187,580 shares of the company’s stock worth $10,835,000 after acquiring an additional 50,057 shares during the period. Finally, AJOVista LLC acquired a new stake in Disc Medicine during the 4th quarter worth approximately $63,000. 83.70% of the stock is owned by institutional investors and hedge funds.

Disc Medicine Stock Up 1.4 %

Shares of NASDAQ IRON opened at $49.41 on Friday. The stock has a market capitalization of $1.22 billion, a price-to-earnings ratio of -14.62 and a beta of 0.57. Disc Medicine, Inc. has a 52 week low of $25.60 and a 52 week high of $77.60. The firm has a 50-day moving average price of $45.33 and a 200 day moving average price of $45.81.

Disc Medicine (NASDAQ:IRON) last issued its earnings results on Thursday, August 8th. The company reported ($1.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.08. Equities research analysts expect that Disc Medicine, Inc. will post -4.47 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. BMO Capital Markets restated an “outperform” rating and set a $70.00 price target (up previously from $50.00) on shares of Disc Medicine in a research note on Monday, June 17th. Cantor Fitzgerald restated an “overweight” rating and issued a $85.00 target price on shares of Disc Medicine in a research note on Tuesday, May 28th. Raymond James lifted their target price on shares of Disc Medicine from $40.00 to $43.00 and gave the company an “outperform” rating in a report on Friday, May 10th. HC Wainwright reissued a “buy” rating and set a $70.00 price target on shares of Disc Medicine in a report on Wednesday, July 10th. Finally, Wells Fargo & Company assumed coverage on Disc Medicine in a report on Thursday. They issued an “overweight” rating and a $75.00 price objective on the stock. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, Disc Medicine currently has an average rating of “Moderate Buy” and a consensus target price of $64.13.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.